Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA approves Zenbexus for multiple myeloma; NSAI seeks buyer for its MDR notified body business

17 August 2026 · By · Wire by Fusion42

Published

17 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at raps.org →

◆ Verified

Fusion42 · 17 August 2026 · Fusion42 review

The US FDA granted accelerated approval to Bristol Myers' drug Zenbexus for multiple myeloma, marking a significant regulatory milestone in cancer treatment. Meanwhile, NSAI is looking for a buyer for its MDR notified body business, indicating a strategic shift in European medical device regulatory support.

This Wire brief sits within Fusion42's coverage of Biotech, and 12 sources have reported it between 13 Aug 2026 and 17 Aug 2026.

◆ ◆ The Wire takeaway

Your biotech firm's path to US market access just got clearer with an FDA green light for a new myeloma drug, while shifts in European notified body services open a gap in MDR certification you might fill.

◆ Coverage

12 sources · first reported 13 Aug 2026 · latest 17 Aug 2026

◆ Topics

BiotechFDAmultiple-myelomadrug-approvalmedical-devicenotified-bodyMDR